Next Article in Journal
Hyperoxia Disrupts Extracellular Signal-Regulated Kinases 1/2-Induced Angiogenesis in the Developing Lungs
Next Article in Special Issue
Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma
Previous Article in Journal
Neuronal Dysfunction Associated with Cholesterol Deregulation
Previous Article in Special Issue
212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2018, 19(5), 1524; https://doi.org/10.3390/ijms19051524

Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer

1
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
2
Department of Chemistry, Drug Discovery Division, Southern Research, Birmingham, AL 35205, USA
3
Division of Pulmonary, Allergy and Critical Care, University of Alabama at Birmingham, Birmingham, AL 35233, USA
*
Author to whom correspondence should be addressed.
Received: 8 May 2018 / Revised: 9 May 2018 / Accepted: 15 May 2018 / Published: 20 May 2018
(This article belongs to the Special Issue Receptor-Targeted Cancer Therapy)
Full-Text   |   PDF [4794 KB, uploaded 20 May 2018]   |  

Abstract

Wnt/β-catenin signaling is upregulated in triple-negative breast cancer (TNBC) compared to other breast cancer subtypes and normal tissues. Current Wnt/β-catenin inhibitors, such as niclosamide, target the pathway nonspecifically and exhibit poor pharmacokinetics/pharmacodynamics in vivo. Niclosamide targets other pathways, including mTOR, STAT3 and Notch. Novel benzimidazoles have been developed to inhibit Wnt/β-catenin signaling with greater specificity. The compounds SRI33576 and SRI35889 were discovered to produce more cytotoxicity in TNBC cell lines than in noncancerous cells. The agents also downregulated Wnt/β-catenin signaling mediators LRP6, cyclin D1, survivin and nuclear active β-catenin. In addition, SRI33576 did not affect mTOR, STAT3 and Notch signaling in TNBC and noncancerous cells. SRI35889 inhibited mTOR signaling less in noncancerous than in cancerous cells, while not affecting STAT3 and Notch pathways. Compounds SRI32529, SRI35357 and SRI35361 were not selectively cytotoxic against TNBC cell lines compared to MCF10A cells. While SRI32529 inhibited Wnt/β-catenin signaling, the compound also mitigated mTOR, STAT3 and Notch signaling. SRI33576 and SRI35889 were identified as cytotoxic and selective inhibitors of Wnt/β-catenin signaling with therapeutic potential to treat TNBC in vivo. View Full-Text
Keywords: receptor-targeted therapy; LRP6; triple-negative breast cancer; Wnt/β-catenin signaling; benzimidazoles receptor-targeted therapy; LRP6; triple-negative breast cancer; Wnt/β-catenin signaling; benzimidazoles
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Gangrade, A.; Pathak, V.; Augelli-Szafran, C.E.; Wei, H.-X.; Oliver, P.; Suto, M.; Buchsbaum, D.J. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2018, 19, 1524.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top